PHARMA

PHARMA

Pharmaceutical Hydrogenation Membrane in South Korea

Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. South Korea's Hydrogen Economy Roadmap is one of the world's most comprehensive, spanning production, distribution, and end-use across transport and power.

Market Context

South Korea

Policy

Hydrogen Economy Roadmap

H₂ Target

6.2 MT hydrogen by 2050, major fuel cell vehicle deployment

3

Cities

5

Industries

Ultra-Clean Hydrogen Source

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

GMP-Compatible On-Site Generation

On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.

Batch-Flexible Operation

Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.

Pharmaceutical Hydrogenation in South Korea’s Hydrogen Market

South Korea's Hydrogen Economy Roadmap is one of the world's most comprehensive, spanning production, distribution, and end-use across transport and power. Ulsan is developing as a hydrogen industrial hub, while Seoul drives policy and R&D. Korean companies are investing in both domestic electrolysis and international hydrogen supply chains.

IONZERA supports Korean electrolyser manufacturers and hydrogen project developers with a high-performance membrane that improves stack efficiency and differentiates Korean-made electrolysers in competitive export markets.

Fuel Cell VehiclesElectrolyser ManufacturingShipbuilding HydrogenSteelPetrochemicals
3x

Lower Resistance

20%

Thinner Profile

PERFORMANCE ADVANTAGE

Why IONZERA for Pharmaceutical Hydrogenation in South Korea

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

Shipping & Logistics

Air freight from India to Seoul/Ulsan in 4-6 business days.

Area Resistance

3x LOWER
Area Specific Resistance ComparisonIONZERA0.09-0.1 Ω·cm²Zirfon0.30 Ω·cm²00.10.20.3 Ω·cm²~3x Lower

Thickness

20% THINNER
Membrane Thickness ComparisonIONZERA350-410 μmZirfon500 μm500 μm scale20-30%thinnerThinner membrane = More compact stacks= Higher power density

Pharmaceutical Hydrogenation Membrane in South Korea Cities

Frequently Asked Questions

Why choose IONZERA for pharmaceutical hydrogenation in South Korea?

IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in South Korea. IONZERA supports Korean electrolyser manufacturers and hydrogen project developers with a high-performance membrane that improves stack efficiency and differentiates Korean-made electrolysers in competitive export markets.

How does IONZERA support Korean electrolyser manufacturers?

IONZERA provides Korean OEMs with a high-performance membrane that enables their electrolysers to achieve lower cell voltages and higher efficiency. This is a meaningful differentiator for Korean electrolysers competing in global markets.

Ready to Start

Request Pharmaceutical Hydrogenation Samples for South Korea

Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for South Korea-based projects.

Request Sample